Viewing Study NCT01810718

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:52 AM
Ignite Modification Date: 2025-12-26 @ 3:53 AM
Study NCT ID: NCT01810718
Status: COMPLETED
Last Update Posted: 2023-03-10
First Post: 2013-02-06
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
Sponsor: Gruppo Italiano Trapianto di Midollo Osseo
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Graft Versus Host Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cGVHD View
None steroid therapy View
None Nilotinib View
None cGVHD steroid refractory View
None intolerant to steroid therapy View
None Tasigna View
None MTD View